Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ewing Sarcoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    98 result(s) found for: Ewing Sarcoma. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2005-003254-10 Sponsor Protocol Number: UCL 08/0230 Start Date*: 2009-08-07
    Sponsor Name:University College London
    Full Title: A Phase II Study to determine the efficacy and safety of conventional dose oral Treosulfan in patients with advanced pre-treated Ewing’s Sarcoma
    Medical condition: Advanced and pre-treated Ewing’s Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015562 Ewing's sarcoma metastatic LLT
    9.1 10015564 Ewing's sarcoma recurrent LLT
    9.1 10015562 Ewing's sarcoma metastatic PT
    9.1 10015564 Ewing's sarcoma recurrent PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-003812-98 Sponsor Protocol Number: BUTTERFLY Start Date*: 2023-04-04
    Sponsor Name:Institute of Mother and Child
    Full Title: To evaluate the efficacy and safety of naxitamab in patients with refractory Ewing's sarcoma.
    Medical condition: Ewing's sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000052-17 Sponsor Protocol Number: PK201301 Start Date*: 2013-10-07
    Sponsor Name:The Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Full Title: Pilot study to investigate the early prediction of toxicity following induction chemotherapy in Ewing’s sarcoma by blood-borne biomarkers and correlation with age-dependent pharmacokinetic variation
    Medical condition: Ewing sarcoma patients
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-008361-35 Sponsor Protocol Number: ISG/AIEOP EW-1 Start Date*: 2008-12-17
    Sponsor Name:ISTITUTI ORTOPEDICI RIZZOLI
    Full Title: PHASE III TRIAL ON THE EFFICACY OF DOSE`S INTENSIFICATION IN PATIENTS WITH NON METASTATIC EWING`S SARCOMA
    Medical condition: HOSPITAL PATIENTS AFFECTED BY EWING`S SARCOMA OR PNET WITH BONE`S INVOLVEMENT
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015560 Ewing's sarcoma LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002793-91 Sponsor Protocol Number: Pervision Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital Tuebingen
    Full Title: Prospective phase I/II trial of an individualized peptide vaccine in pediatric and AYA patients with metastasized fusion-driven sarcomas following standard treatment
    Medical condition: The trial will include patients with so called "fusion-driven", metastatic sarcomas of the following types: - Ewing sarcoma, - alveolar rhabdomyosarcoma - or synovial sarcoma who are in first or s...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065867 Alveolar rhabdomyosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003570-31 Sponsor Protocol Number: ONITT Start Date*: 2021-07-19
    Sponsor Name:St. Jude Children's Research Hospital
    Full Title: A Randomized Phase I/II Study of Onivyde in Combination with Talazoparib or Temozolomide in Children and Young Adults with Recurrent Solid Malignancies and Ewing Sarcoma
    Medical condition: EWING SARCOMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015562 Ewing's sarcoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015564 Ewing's sarcoma recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2007-003940-30 Sponsor Protocol Number: NO21157 Start Date*: 2008-05-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the treatment of patients with recurrent or refractory Ewing’s sarcoma, osteosarc...
    Medical condition: Ewing’s sarcoma and other sarcoma subtypes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015560 Ewing's sarcoma LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) ES (Completed) SE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002107-17 Sponsor Protocol Number: RG_11-152 Start Date*: 2013-02-01
    Sponsor Name:University of Birmingham
    Full Title: International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours
    Medical condition: Ewing's Sarcoma Family of Tumours
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Completed) CZ (Completed) IE (Completed) HU (Completed) NL (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004734-11 Sponsor Protocol Number: J1S-MC-JP04 Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Relapsed or Refractory Ewing's Sarcoma
    Medical condition: Ewing's Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000616-28 Sponsor Protocol Number: OCTO_038 Start Date*: 2013-08-22
    Sponsor Name:University of Oxford
    Full Title: Phase II trial of Linsitinib (anti-IGFR/IR) in patients with relapsed and/or refractory Ewing Sarcoma
    Medical condition: Relapsed and/or refractory Ewing sarcoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005541-50 Sponsor Protocol Number: ESP1/SARC025 Start Date*: 2016-09-13
    Sponsor Name:Sarcoma Alliance for Research through Collaboration (SARC)
    Full Title: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor, Niraparib and Temozolomide and/or Irinotecan in Patients with Previously Treated, incurable Ewing Sarcoma
    Medical condition: relapsed Ewing sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015562 Ewing's sarcoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015564 Ewing's sarcoma recurrent PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005554-62 Sponsor Protocol Number: ASSG03 Start Date*: 2012-04-16
    Sponsor Name:Australian Sarcoma Group (ASSG)
    Full Title: Pharmacokinetics and Pharmacodynamics of Doxorubicin in Children, Adolescents and young adults with Newly Diagnosed Osteosarcoma, Ewing Family of Tumours and Hodgkin Lymphoma A Multi-Institutional ...
    Medical condition: Ewing family of tumours Osteosarcoma Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020328 Hodgkin's lymphoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015570 Ewing's tumour LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031291 Osteosarcoma LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022221-15 Sponsor Protocol Number: PM104-B-003-10 Start Date*: Information not available in EudraCT
    Sponsor Name:Pharma Mar S.A., Sociedad Unipersonal
    Full Title: Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing...
    Medical condition: Advanced and/or Metastatic Ewing Family of Tumors (EFT)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10057846 Primitive neuroectodermal tumour LLT
    12.1 10015560 Ewing's sarcoma LLT
    12.1 10015759 Extra-osseous Ewing's sarcoma LLT
    12.1 10057656 Askin's tumour LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2023-000169-14 Sponsor Protocol Number: INES Start Date*: 2023-05-03
    Sponsor Name:Fondazione Santobono Pausilipon ONLUS
    Full Title: Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing Sarcoma
    Medical condition: Ewing Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003595-12 Sponsor Protocol Number: ADVL1322-VEG116731 Start Date*: 2013-09-04
    Sponsor Name:GlaxoSmithKline
    Full Title: A Phase II Study of Pazopanib in Children, Adolescents and Young Adults with Refractory Solid Tumors.
    Medical condition: relapsed solid tumours in children, adolescents and young adults.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA CZ (Completed) SK (Completed) ES (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000062-11 Sponsor Protocol Number: INCB59872-103 Start Date*: 2019-05-30
    Sponsor Name:Incyte Corporation
    Full Title: An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma
    Medical condition: Relapsed or Refractory Ewing Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005339-22 Sponsor Protocol Number: REGBONE Start Date*: Information not available in EudraCT
    Sponsor Name:Instytut Matki i Dziecka
    Full Title: To evaluate the efficacy and safety of regorafenib in patients with refractory primary bone tumors.
    Medical condition: Refractory primary bone tumors
    Disease: Version SOC Term Classification Code Term Level
    27.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015562 Ewing's sarcoma metastatic PT
    27.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015564 Ewing's sarcoma recurrent PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031294 Osteosarcoma metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031296 Osteosarcoma recurrent PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000383-15 Sponsor Protocol Number: BAY80-6946/19176 Start Date*: 2023-06-05
    Sponsor Name:Bayer AG
    Full Title: A non-randomized, open-label, multi-center, Phase I/II study of PI3K inhibitor copanlisib in pediatric patients with relapsed/refractory solid tumors or lymphoma
    Medical condition: Relapsed or refractory solid tumors or lymphoma in children Neuroblastoma Osteosarcoma Rhabdomyosarcoma Ewing sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025310 Lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031291 Osteosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039022 Rhabdomyosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-004486-17 Sponsor Protocol Number: A4021020 Start Date*: 2008-08-26
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 1/PHASE 2 STUDY OF CP-751,871 IN PATIENTS WITH RELAPSED AND/OR REFRACTORY EWING’S SARCOMA FAMILY OF TUMORS
    Medical condition: Ewing's sarcoma family tumours
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015562 Ewing's sarcoma metastatic PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Not Authorised) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000854-85 Sponsor Protocol Number: CA045-020 Start Date*: 2021-04-19
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase 1/2 Study of Bempegaldesleukin in Combination with Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Malignancies (PIVOT IO 020)
    Medical condition: Recurrent or Refractory pediatric cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015560 Ewing's sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039022 Rhabdomyosarcoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.0 10005329 - Blood and lymphatic system disorders 10025322 Lymphomas non-Hodgkin's unspecified histology HLGT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024329 Leukemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014967 Ependymoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007958 Central nervous system neoplasm PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Prematurely Ended) DE (Completed) IT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:08:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA